VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif. , March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients.
VERDI Solutions, headquartered in Vienna, Austria , is pioneering personalized cancer treatment by integrating artificial intelligence (AI) and advanced cloud computing to accelerate the development and implementation of personalized cancer vaccines. By combining computerized vaccine design with real-world data collection and clinical trials, VERDI is making personalized cancer vaccines accessible to more patients worldwide. At the core of VERDI's innovation is its cloud-computing platform, which enables the rapid development of personalized peptide vaccines tailored to individual cancer patients.
Additionally, the company is developing off-the-shelf cancer vaccines, paired with companion diagnostics to identify likely responders and optimize treatment outcomes. In some European countries, oncologists may administer personalized cancer vaccines under Individueller Heilversuch (Individual Healing Attempt), which allows physicians to prescribe individualized treatments for patients with life-threatening conditions who lack satisfactory the.
